Emerald Advisers, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Emerald Advisers, LLC

$2.92 Billion
Q3 2025

A detailed history of Emerald Advisers, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 1,695 shares of ALNY stock, worth $761,326. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,695

Previous 1,941 12.67%

Holding current value

$761,326

Previous $632,000 22.15%

% of portfolio

0.03%

Previous 0.02%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 30, 2025	SELL	$311.12 - $482.13 $76,535 - $118,603	-246 Reduced 12.67%	1,695 $772,000
Q2 2025 Aug 04, 2025	BUY	$224.32 - $326.09 $99,822 - $145,110	445 Added 29.75%	1,941 $632,000
Q1 2025 May 01, 2025	SELL	$233.07 - $290.7 $19,577 - $24,418	-84 Reduced 5.32%	1,496 $403,000
Q4 2024 Feb 11, 2025	BUY	$232.27 - $300.43 $696 - $901	3 Added 0.19%	1,580 $371,000
Q3 2024 Oct 29, 2024	SELL	$233.81 - $287.01 $9,586 - $11,767	-41 Reduced 2.53%	1,577 $433,000

Q2 2024 Aug 06, 2024	SELL	$143.31 - $247.0 $64,776 - $111,644	-452 Reduced 21.84%	1,618 $393,000
Q1 2024 May 08, 2024	SELL	$146.51 - $198.2 $3,516 - $4,756	-24 Reduced 1.15%	2,070 $309,000
Q4 2023 Feb 05, 2024	SELL	$151.41 - $196.57 $140,054 - $181,827	-925 Reduced 30.64%	2,094 $400,000
Q3 2023 Oct 26, 2023	SELL	$170.77 - $211.65 $11,441 - $14,180	-67 Reduced 2.17%	3,019 $534,000
Q2 2023 Jul 25, 2023	SELL	$185.01 - $212.05 $8,510 - $9,754	-46 Reduced 1.47%	3,086 $586,000
Q1 2023 May 04, 2023	BUY	$182.66 - $235.53 $105,029 - $135,429	575 Added 22.49%	3,132 $627,000
Q4 2022 Feb 03, 2023	SELL	$185.53 - $241.31 $7,977 - $10,376	-43 Reduced 1.65%	2,557 $607,000
Q3 2022 Oct 25, 2022	SELL	$138.54 - $232.0 $2,909 - $4,872	-21 Reduced 0.8%	2,600 $520,000
Q2 2022 Jul 29, 2022	SELL	$120.42 - $169.29 $37,932 - $53,326	-315 Reduced 10.73%	2,621 $382,000
Q1 2022 Apr 29, 2022	SELL	$127.18 - $173.91 $6,867 - $9,391	-54 Reduced 1.81%	2,936 $479,000
Q4 2021 Feb 02, 2022	SELL	$159.56 - $209.29 $6,701 - $8,790	-42 Reduced 1.39%	2,990 $507,000
Q3 2021 Oct 28, 2021	SELL	$169.75 - $207.73 $179,425 - $219,570	-1,057 Reduced 25.85%	3,032 $572,000
Q1 2021 Apr 29, 2021	SELL	$126.83 - $175.69 $22,829 - $31,624	-180 Reduced 4.22%	4,089 $577,000
Q4 2020 Jan 29, 2021	SELL	$122.97 - $147.0 $414,408 - $495,390	-3,370 Reduced 44.12%	4,269 $555,000
Q3 2020 Oct 28, 2020	SELL	$121.19 - $165.49 $10,907 - $14,894	-90 Reduced 1.16%	7,639 $1.11 Million
Q2 2020 Jul 28, 2020	SELL	$104.21 - $156.44 $150,583 - $226,055	-1,445 Reduced 15.75%	7,729 $1.15 Million
Q1 2020 Apr 30, 2020	SELL	$93.12 - $133.99 $10,336 - $14,872	-111 Reduced 1.2%	9,174 $999,000
Q4 2019 Jan 29, 2020	SELL	$74.51 - $124.23 $103,196 - $172,058	-1,385 Reduced 12.98%	9,285 $1.07 Million
Q3 2019 Oct 31, 2019	SELL	$70.9 - $87.82 $105,924 - $131,203	-1,494 Reduced 12.28%	10,670 $858,000
Q2 2019 Jul 31, 2019	SELL	$65.86 - $92.79 $72,050 - $101,512	-1,094 Reduced 8.25%	12,164 $883,000
Q1 2019 May 01, 2019	BUY	$72.76 - $93.45 $5,311 - $6,821	73 Added 0.55%	13,258 $1.24 Million
Q4 2018 Jan 30, 2019	SELL	$62.67 - $88.33 $315,418 - $444,564	-5,033 Reduced 27.63%	13,185 $961,000
Q3 2018 Oct 31, 2018	BUY	$87.52 - $122.67 $42,272 - $59,249	483 Added 2.72%	18,218 $1.59 Million
Q2 2018 Jul 31, 2018	BUY	$88.31 - $107.8 $341,583 - $416,970	3,868 Added 27.89%	17,735 $1.75 Million
Q1 2018 Apr 26, 2018	SELL	$115.92 - $148.54 $115,456 - $147,945	-996 Reduced 6.7%	13,867 $1.65 Million
Q4 2017 Feb 05, 2018	SELL	$114.49 - $139.98 $106,475 - $130,181	-930 Reduced 5.89%	14,863 $1.89 Million
Q3 2017 Oct 30, 2017	BUY	$72.53 - $118.27 $1.15 Million - $1.87 Million	15,793	15,793 $1.86 Million

Others Institutions Holding ALNY

# of Institutions

916

Shares Held

117M

Call Options Held

1.25M

Put Options Held

1.49M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.

Account

Emerald Advisers, LLC Alnylam Pharmaceuticals, Inc. Transaction History